Austin Health

Title
DEPDC5 as a potential therapeutic target for epilepsy.
Publication Date
2017-06
Author(s)
Myers, Kenneth A
Scheffer, Ingrid E
Subject
DEPDC5
GATOR1
NPRL2
NPRL3
cortical dysplasia
focal epilepsy
mechanistic target of rapamycin
rapamycin
tuberous sclerosis
Type of document
Journal Article
OrcId
0000-0002-2311-2174
DOI
10.1080/14728222.2017.1316715
Abstract
Dishevelled, Egl-10 and Pleckstrin (DEP) domain-containing protein 5 (DEPDC5) is a protein subunit of the GTPase-activating proteins towards Rags 1 (GATOR1) complex. GATOR1 is a recently identified modulator of mechanistic target of rapamycin (mTOR) activity. mTOR is a key regulator of cell proliferation and metabolism; disruption of the mTOR pathway is implicated in focal epilepsy, both acquired and genetic. Tuberous sclerosis is the prototypic mTOR genetic syndrome with epilepsy, however GATOR1 gene mutations have recently been shown to cause lesional and non-lesional focal epilepsy. Areas covered: This review summarizes the mTOR pathway, including regulators and downstream effectors, emphasizing recent developments in the understanding of the complex role of the GATOR1 complex. We review the epilepsy types associated with mTOR overactivity, including tuberous sclerosis, polyhydramnios megalencephaly symptomatic epilepsy, cortical dysplasia, non-lesional focal epilepsy and post-traumatic epilepsy. Currently available mTOR inhibitors are discussed, primarily rapamycin analogs and ATP competitive mTOR inhibitors. Expert opinion: DEPDC5 is an attractive therapeutic target in focal epilepsy, as effects of DEPDC5 agonists would likely be anti-epileptogenic and more selective than currently available mTOR inhibitors. Therapeutic effects might be synergistic with certain existing dietary therapies, including the ketogenic diet.
Link
Citation
Expert opinion on therapeutic targets 2017; 21(6): 591-600
Jornal Title
Expert opinion on therapeutic targets

Files:

NameSizeformatDescriptionLink